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ABSTRACT: The preparative resolution by preferential crystal-
lization (PC) of proxyphylline has been achieved despite the 
existence of a stable racemic compound. This is enabled through 
the careful selection of a solvent in which both the racemic com-
pound and the metastable conglomerate possess a low nucleation 
rate. Induction time (IT) measurements in isobutyl alcohol show 
that a highly supersaturated solution (β = 2.3) remains clear for 
almost 1 hour at 20 mL scale, revealing a slow nucleation rate. 
Seeding the supersaturated solution with the pure enantiomer 
triggered its crystallization and isothermal and polythermic modes 
of PC were successfully implemented. Alongside the reported 
case of diprophylline, this study opens opportunities to broaden 
the application of PC towards slowly crystallizing racemic com-
pound. 
Keywords: Preferential Crystallization, Nucleation Inhibition, 
Proxyphyline, Metastable Conglomerate. 
1.  INTRODUCTION 
In the field of pharmaceutical industry, around 56% of the mar-
keted drugs are chiral compounds,1 of which ca. 80% are formu-
lated as racemic mixtures, i.e. equimolar mixtures of both enanti-
omers.2 Although two enantiomers have the same physico-
chemical properties, their biological activities (including toxicity) 
can be different.3 Nowadays, the biological activity of each anti-
pode has to be established and, if different, any new chiral active 
pharmaceutical ingredient has to be developed from the most 
active enantiomer.4 The two main strategies to obtain pure enanti-
omer are: (i) the direct manufacturing of a single enantiomer by 
means of asymmetric synthesis5 and (ii) the separation of the 
enantiomers from their racemic mixture, sometimes combined 
with the racemization of the undesired enantiomer (i.e. the 
distomer).6  
To access to pure enantiomers, different methods exist. The de-
sired enantiomer can be directly synthesized by asymmetric syn-
thesis or by starting from a stock of readily available enantiopure 
sources (chiral pool synthesis7). Such synthesis is often complex, 
expensive and require many different reagents and processing 
stages. Enantiopure compound can also be achieved by various 
separation methods, including chiral chromatography8 and enzy-
matic resolution.9 However, crystallization techniques remain the 
preferred route at the industrial scale for their high selectivity and 
low cost. Besides Pasteurian Resolution and Deracemization,6 
Preferential Crystallization10 (PC hereafter) is an attractive pro-
cess with high selectivity and efficiency. Indeed, successive crys-
tallization of the two enantiomers –supposed here non-
racemizable during the crystallization– allows them to be separat-
ed quantitatively. Such PC processes actually consist of out-of-
equilibrium stereoselective crystallizations with a high degree of 
chiral discrimination, triggered by seeding a racemic or slightly 
enriched supersaturated solution with single enantiomer seed 
crystals.11 The implementation of PC is simplified by the 
knowledge of the heterogeneous equilibria between both enantio-
mers in the solid state since it is commonly thought that PC is 
only applicable when the racemic mixture crystallizes as a con-
glomerate, i.e. a physical mixture of enantiopure crystals. For 
chiral compounds giving rise to a stable racemic compound (i.e., a 
1:1 defined compound between both enantiomers) or solid solu-
tion (i.e., a single solid phase which does not discriminate be-
tween enantiomers), PC is assumed to be non-applicable. This 
strongly limits the scope of PC as only roughly 5% of racemic 
mixtures crystallize as conglomerates whereas the vast majority of 
around 95% exist as racemic compounds. Therefore, the strategy 
for the implementation of PC in case of racemic compound form-
ing systems is usually to convert the racemic compound into a 
diastereomer solid or a conglomerate by using a crystallization 
partner in order to form a salt,12 a solvate13 or a cocrystal.14 The 
scope of PC would obviously be widened if this resolution meth-
od could be implemented for chiral compounds forming stable 
racemic compounds. 
In 2013, we reported that the chiral compound Diprophylline 
(Scheme 1a, DPL hereafter)15 exhibits a rich solid state landscape 
with no less than four crystal forms, including a stable racemic 
compound, two metastable solid solutions and a metastable con-
glomerate. In the course of this study, we found that a solution of 
racemic DPL in polar solvents such as water, DMSO and DMF 
can remain highly supersaturated for several hours before any 
spontaneous nucleation. This large metastable zone width 
(MSZW hereafter), in which the nucleation of the stable form 
(and any other form) is hindered, served the successful implemen-
 tation of PC, leading to a pure enantiomer product by using this 
unconventional process.  
Beside the careful analysis of chiral discrimination 
mechanism16 it can be presumed that the key parameter for the 
successful implementation of PC despite the absence of a stable 
conglomerate is the use of a solvent in which spontaneous nuclea-
tion is strongly delayed, giving rise to a large MSZW, even at 
high supersaturation. This feature allows the use of metastable 
equilibria associated to the conglomerate whereas the stable 
equilibria of the racemic compound can be overpassed. Since the 
solubility of the conglomerate in such situation is necessarily 
larger than that of the racemic compound, the concentration 
should be high enough to reach a value at which there exists a 
sufficient supersaturation with respect to the conglomerate.  
Assuming that a solvent fulfilling the above criteria can be 
identified, the applicability of PC might be envisaged for any 
chiral compound crystallizing as a stable racemic compound, 
which would considerably expand the scope of chiral resolution 
by PC. The associated strategy should therefore involve a screen-
ing procedure aiming at identifying a solvent in which a large 
MSZW can be reached at the working temperature, via the meas-
urement of induction times.17 
Scheme  1. Chemical structure of (a): (RS)-DPL and (b): 
(RS)-PXL. The chiral center is denoted with a star. 
 
The present paper reports on the application of direct PC of the 
racemic compound proxyphylline. The selected compound is 
proxyphylline (PXL hereafter, Scheme 1b) a xanthine-type bron-
chodilator drug from the series of theophylline derivatives that 
acts as a cardiac stimulant, vasodilator and bronchodilator18 close-
ly related to DPL. This work gives a proof-of-concept for PC of a 
stable racemic compound and describes a basic process design 
procedure including a solvent selection procedure for PXL as well 
as an approach to identify optimal PC process conditions in the 
selected solvent.  
2.  MATERIALS AND METHODS 
2.1. Materials. Racemic 7-(2-Hydroxypropyl) theophylline 
(purity >98.0%) was purchased from TCI EUROPE (Zwijndrecht-
Belgium) and used as received. HPLC grade solvents and other 
reagents were purchased and used as received. 
2.2. Synthesis of the Pure Enantiomer of Proxyphylline. 
Enantiopure proxyphylline was synthesized by analogy with a 
published procedure19 from theophylline and enantiopure propyl-
ene oxide. A mixture of anhydrous theophylline (5 g, 27.75 
mmol), (R)-propylene oxide (purity 99 %, ee 97%) (5 g, 86.08 
mmol, 6 mL) and a catalytic amount of triethylamine (1 g, 7.17 
mmol, 1 mL) in methanol (40 mL) was stirred for 3 h at reflux 
until complete dissolution. After cooling the mixture, the solvent 
was evaporated under reduced pressure. Then, 20 mL of methanol 
were added, and the flask was stored in the fridge (-18 °C) for 4 h 
until crystallization. The obtained solid was filtered off and 
washed with cold ethanol (15 mL) yielding the desired product 
(S)-7-(2-Hydroxypropyl) theophylline, (S)-PXL, as a white crys-
talline solid (4 g, 16.78 mmol, yield = 61%) - mp 149.5 °C {Ref.20 
142-150 °C and Ref.21 150.5-151.5 °C}; [α]D
20 = – 53° (c = 1.00 
mg/mL, CHCl3) {Ref.
19 : [α]D
20 = – 54° (c = 1.00 mg/mL, CHCl3), 
98% ee}. ee HPLC = (-) 99.9 %.   
1H NMR (MHz) δ = 1.28 (d, 3H), 3.42 (s, 3H), 3.60 (s, 3H), 
4.07-4.3 (m, 2H), 4.45-4.53 (m, 1H), 7.62 (s, 1H).   
2.3. Chiral HPLC. Purity of the obtained enantiomer was de-
termined with chiral high-performance liquid chromatography (C-
HPLC) using a CHIRALPAK IC column (DAICEL group, Chiral 
Technologies Europe), 250 × 4.6 mm. The mobile phase was a 
heptane:ethanol mixture (7.5:2.5, v:v), and the flow rate was 1 
mL/min. The used wavelength for UV detection was 273 nm at 20 
°C. Under these conditions, retention times of 15 and 18 min were 
obtained for (R)-PXL and (S)-PXL respectively. An offline C-
HPLC analysis was used to monitor the enantiomeric excess (ee) 
of the liquid phase as function of time during the PC. 
2.4. X-Ray diffractometry (XRPD). X-ray Powder Diffraction 
(XRPD) analyses were performed at room temperature using a D8 
Discover diffractometer (Bruker analytic X-ray Systems, Germa-
ny) with Bragg-Brentano geometry. The instrument is equipped 
with a copper anticathode (40 kV, 40 mA, Kα radiation (λ 
=1.5418 Å)), and a lynx eye linear detector. The diffraction pat-
terns were recorded with a scan rate of 0.04° (2θ) in the angular 
range of 3-30° 2θ, with a counting time of 4s per step. 
2.5. Solubility Measurements. The solubilities of racemic 
PXL in 22 different solvents were measured at 20 °C by the 
standard gravimetric method.22 A suspension of racemic PXL was 
prepared in a solvent and stirred at 700 rpm. Temperature was 
controlled using a thermostated double-jacket glass vessels. After 
equilibration for more than 2 hours, the suspension was filtered, 
the solid phase in equilibrium with the solution was verified by 
XRPD and the saturated liquid phase was weighed before and 
after evaporation. The solubility s* was calculated in weight 
percent (w%) by equation 1 with m the mass of the the dissolved 
solid and ms the mass of  the saturated solution.  
s* = 
 
   
 x 100        Equation 1 
2.6. Induction Time Measurements. The induction time (ti) 
i.e. the time required to detect spontaneous crystallization in a 
supersaturated solution, was determined at different 
supersaturation ratios and in different solvents. For each sol-
vent/supersaturation couple, a suitable mass of racemic PXL was 
dissolved in a suitable mass of solvent by heating. The solution 
was then introduced in 4 different 1.5 mL glass vials equipped 
with magnetic stirrers. The vials were then placed in a Crystal16 
(Technobis, The Netherlands)17 and stirred (800 rpm) 10 °C above 
their saturation temperature for at least 90 min. The clear solu-
tions were then cooled down to 20 °C with a cooling rate of 5 
°C/min. The moment at which the set temperature (20 °C) was 
reached is taken as time zero (t0). The vials were kept at 20 °C 
until spontaneous crystallization was detected via the decrease of 
light transmission through the sample. The difference between the 
moment when the transmissivity started to decrease and t0 was 
taken as ti. Once the different samples crystallized, the vials were 
reheated above their clear point and the procedure was repeated to 
ensure statistical reproduction.  
The solvents that gave the longest ti values were also tested at a 
larger scale of 10-20 mL. For this purpose, a suitable amount of 
solvent was added to a known amount of racemic PXL and the 
mixture was stirred for at least 1h at high temperature to ensure 
complete dissolution. Then the solution was cooled down to the 
crystallization temperature Tc (10 or 20 °C) and the ti value was 
taken as the time lapse between the moment at which the solution 
reached Tc and the moment at which spontaneous crystallization 
occurred, detected visually. Each measurement was repeated at 
 least three times using the same solution. Systematically, the 
racemic compound of PXL crystallized. 
2.7. Determination of ternary isotherms between (R)-PXL, 
(S)-PXL and isobutyl alcohol. In order to determine isothermal 
ternary phase diagrams, the solubility values were determined in 
isobutyl alcohol at 25 and 10 °C using the regular gravimetric 
method for (i) the stable racemic compound of PXL (RC-PXL), 
(ii) the pure enantiomer (R)-PXL (PE-PXL), (iii) the doubly satu-
rated solution containing  (R)-PXL and RC-PXL, and (iv) the 
equimolar mixture of (R)- and (S)-PXL (i.e., the metastable con-
glomerate (MC-PXL)). Concerning (iii), the enantiomeric compo-
sition of the dry extract was measured by chiral HPLC. For (iv), 
the solubility of the metastable conglomerate was determined by 
stirring an equimolar mixture of (R) and (S)-PXL (prepared man-
ually) in a small volume of isobutyl alcohol for a few minutes 
under a controlled constant temperature. The solid phase in equi-
librium with the saturated solution was verified systematically by 
XRPD. 
  2.8. Preferential Crystallization. Preferential Crystallization 
(PC) experiments using (RS)-PXL were performed in isobutyl 
alcohol using a 50 mL glass tube equipped with a magnetic stir-
ring bar. The temperature was controlled by a cryothermostat (+/- 
1°C). Seeding was performed once the solution reached the de-
sired Tc in order to start the preferential crystallization. Seeds used 
in these experiments were obtained by recrystallization from 
methanol. The seeds were dried and manually ground with a 
mortar and a pestle (Figure S2 presents a microscopy picture of 
the seed material). Seeding was performed by direct introduction 
of the solid particles in the solution. The absence of agglomerates 
was controlled systematically.  
The enantiomeric excess in the liquor and in the solid phase 
during the process was monitored by offline chiral chromatog-
raphy. Vacuum filtration was performed at the end of each PC and 
the solid phase was washed with cold heptane (at around -10°C). 
The purity and solid-state form of the collected crystals were 
determined by respectively chiral chromatography and XRPD. 
Several cycles of PC were performed in two modes:10,23 Seeded 
Isothermal Preferential Crystallization (SIPC) and Seeded 
Polythermic Programmed Preferential Crystallization (S3PC).  
 
3. RESULTS AND DISCUSSION 
 3.1. Solvent Selection. The starting assumption of this work is 
that the key parameter for the successful implementation of PC 
for a stable racemic compound-forming system is the selection of 
a solvent in which the spontaneous nucleation of the stable crystal 
form as well as the metastable conglomerate are kinetically inhib-
ited. If a highly supersaturated solution can be maintained for a 
sufficiently long period of time in this solvent, seeding with a 
single enantiomer would mainly promote its growth whereas the 
stable racemic compound or the counter enantiomer would not 
nucleate. Obviously, in the case of a racemic forming system, PC 
can only be envisaged if the solution is also supersaturated with 
reference to the metastable conglomerate.   
In a preliminary step, a large collection of solvents was tested 
for suitable solubility. Those solvents for which the PXL solubili-
ty at 20 °C lies between 1.5 and 50 w% were further investigated 
by determining induction time ti at 1 mL scale (see Figure S3 and 
Table S1 in supporting information). For samples showing large ti 
values at 1 mL scale, tests were made at larger scale (10 or 20 
mL), at a supersaturation ratio 1.5≤≤2.5 in respect to the stable 
racemic compound (Table 1). Spontaneous nucleation of RC-PXL 
occurred much more rapidly at larger scales and this type of de-
pendency of the nucleation rate with crystallizer size has been 
discussed elsewhere.24  
3.2. Design of Preferential Crystallization processes. Despite 
ti values larger than 180 and 100 minutes found in water and 1-
propanol respectively, preliminary PC attempts were unsuccessful 
due to the primary heterogeneous crystallization and nucleation of 
the stable racemic compound immediately after seeding with 
crystals of pure enantiomer. This spontaneous crystallization was 
detected by means of X-ray powder diffraction (XRPD) of the 
solid phase sampled during the experiment. These solvents were 
therefore discarded. This shows that a large metastable zone width 
is necessary but not sufficient to ensure the success of PC under 
these particular circumstances. Based on the promising ti results, 
it was chosen to further investigate the resolution process in iso-
butyl alcohol (IBA). 
 
Table 1. Induction time for (RC)-PXL in different solvents. 
Solvent 
Tc 
(°C) 
s* 
(w%) 
[c] 
ti 
(min) 
Methanol 20 11.7 1.5 20[a] 
2-butanol 20 4.6 2.3 20 [b] 
Ethanol 20 5.5 1.5 20 [b] 
1,4-dioxane 20 6.6 1.5 15 [b] 
Tetrahydrofuran 20 5.6 1.5 5[a] 
DMSO 20 21.4 2 15 [b] 
Ethyl acetate 20 1.8 1.7 2[a] 
Acetonitrile 20 6 2 2[a] 
Water 20 47.7 2.5 180[a] 
1-propanol 20 3.2 2 100[a] 
Isobutyl alcohol 
20 2.9 2.3 60[a] 
10 2.1 2.3 60[a] 
[a]20 mL scale, [b] 10 mL scale, [c] maximum 
supersaturation ratio tested. 
3.2.1. Solubility Measurements and Ternary Isotherms (R)-
PXL/(S)-PXL/IBA. Knowledge of the ternary phase diagram is 
needed in order to rationalize any resolution procedure by PC. 
PXL can exist as a pure enantiomer crystal form (PE-PXL) and, at 
the racemic composition, either as a stable racemic compound 
(RC-PXL) or as a metastable conglomerate (MC-PXL). The 
solubility curves of the three crystal forms in the solvent IBA are 
shown in Figure 1 (the corresponding solubility values are given 
in Table S2). 
  
Figure 1. Solubility curves of the three crystal forms of PXL in 
IBA as function of temperature. PE-PXL: pure enantiomer of 
PXL, RC-PXL: racemic compound, MC-PXL: metastable con-
glomerate. Colored lines are a guide to the eye. 
 
Figure 2. A: Ternary solubility phase diagram including the metastable solubility lines (dashed lines) for (R) and (S)-PXL in IBA at 10 and 
25 °C used as Tc for SIPC and S3PC respectively (W is for weight fraction). B: Performance of PC process for enantioseparation in SIPC 
mode, C: Performance of PC process in S3PC mode. Signification of (a,b,c,d and e) is described in the text.   
As expected, the s* of the metastable conglomerate MC-PXL in 
IBA is higher than that of the racemic compound RC-PXL and the 
solubility difference substantially increases with temperature. For 
instance, at 10°C s* of MC-PXL is 1.3 times higher than that of 
RC-PXL and roughly twice that of PE-PXL. At 40 °C the s* of 
MC-PXL becomes twice higher than that of RC-PXL and trice 
that of PE-PXL.  
These solubility data were used for the construction of the ter-
nary isothermal sections at 10 and 25 °C (Figure 2) (temperature 
used for PC processes) and to plot the metastable solubility lines 
representing the virtual crystallization limits. The slope of the 
solubility curves of the enantiomers can be described using the 
molar solubility ratio mol, defined as the solubility of the racemic 
conglomerate divided by the solubility of the pure enantiomer. As 
discussed by Jacques et al.,25 the PC process is less efficient when 
mol is higher than 2. In the present case, mol ratio drops from 2.8 
at 40°C to 1.8 at 10°C which indicates that PC of RC-PXL in IBA 
is more favorable at lower temperature.  
 Based on the ternary isothermal sections, two processes of PC 
have been used to resolve PXL in IBA: Seeded Isothermal Prefer-
ential Crystallization (SIPC) and Seeded Programmed 
Polythermic Preferential Crystallization (S3PC).10 In Figure 2 the 
initial concentration of RC-PXL in IBA (Co) used in this work is 
represented with black and red triangles respectively for SIPC and 
S3PC modes. Under these conditions, the solution is supersaturat-
ed at the crystallization temperature (10 or 20°C) regarding both 
RC-PXL and MC-PXL. 
3.2.2. Preferential Crystallization of PXL by SIPC. As evi-
denced in Table 1, a supersaturated solution of racemic PXL in 
IBA with a supersaturation ratio of = 2.3 at 20 mL scale and at 
10 °C takes at least 1h to crystallize spontaneously as RC-PXL 
which prompted us to perform a resolution procedure using the 
SIPC mode. Four SIPC experiments were monitored as function 
of time with various seed mass using the conditions in Table 2. 
The principle of SIPC, is presented in Figure 2.B which depicts 
the envisaged evolution of the composition of the mother liquor 
during the process (it is exemplified by the SIPC experiment 
using 150 mg of seeds). The starting solution saturated with RC-
PXL at Ts=35 °C (s*=5 w%) is indicated as a black triangle in 
Figure 2. After rapid cooling to Tc=10 °C (s*=2.1 w%, = 2.3 
with reference to RC-PXL and 1.8 with reference to MC-PXL), 
the supersaturated solution is seeded with 150 mg of fine particles 
of the pure R enantiomer. This induces the stereoselective crystal-
lization of this enantiomer while the enantiomeric excess of the 
mother liquor evolves from eea = 0 % (point a in Figure 2.B) to 
eeb = (-) 5.10 % (point b in Figure 2.B) within 20 minutes. At (b), 
the system is filtered resulting in, 212.2 mg of crystals with an 
enantiomeric purity of 91.3%. The liquor is then compensated 
with 47.73 mg of RC-PXL and with solvent, thus moving from 
point b to point c (eec = (-) 3.80 %). After homogenization of the 
system at 35 °C, the liquor, enriched in (S) enantiomer is cooled 
to 10 °C and seeded with 150 mg of (S)-DPL to complete the 
cycle and move from (-) 3.15 % eec to (-) 0.15 % eed (point d in 
Figure 2.B) within 30 minutes, 201.0 mg of solid was collected 
with an ee of (+) 89.7 %. To move from point d to point e (Figure 
2.B), the liquor is again compensated with 30.29 mg of RC-PXL 
and solvent, homogenized at 35 °C than cooled down to 10 °C to 
start a new cycle. The process can thus be continuously cyclized.  
Table 2. Starting Experimental Conditions for SIPC. mIBA: 
mass of isobutyl alcohol, mRC: initial mass of RC-PXL 
dissolved in solvent, Co: initial total concentration of the 
solution, Ts: initial saturation temperature, Tc: constant 
crystallization temperature,        
 : solubility of RC-PXL 
at 10°C in IBA,        
 : solubility of MC-PXL at 10°C in 
IBA,  Ytheo: theoretical yield defined as 
           
    
( x100). 
Conditions SIPC 
mIBA (g) 17 
mRC (mg) 894 
Co (w%) 5.0 
Ts (°C) 35 
Tc (°C) 10 
   10° 
*  2.1 
   10° 
*  2.7 
Ytheo (%) 20 
 
In order to determine the suitable balance between seed mass 
and duration before filtration, the impact of the seed amount on 
the entrainment effect was assessed by using various amounts of 
seeds ranging from 50 to 150 mg. The enantiomeric excess values 
in the solution as a function of time are shown in Figure 3a. After 
seeding with (S) enantiomer seed crystals, the solution is progres-
sively enriched in the counter (R) enantiomer. This is a clear 
indication that an out-of-equilibrium stereoselective crystalliza-
tion of (S)-PXL is occurring in spite of the existence of the stable 
racemic compound. 
One can also see that the higher the seed mass, the higher and 
the faster the liquor gets enriched in the opposite enantiomer until 
the seed mass reaches 100 mg. This can be either because (S) 
enantiomer crystallize faster from solution due to larger seed 
crystal surface area, or because less (RS) is formed when more 
seeds are added, so that less (R) is removed from solution.  
In the profile given in Figure 3a (red curve), one can see that 
the entrainment starts after seeding with 80 mg of (S)-seeds, yet 
after 60-70 minutes the ee of the liquid phase decreases. This 
probably results from the heterogeneous nucleation of RC-PXL, 
and possibly of the counter enantiomer. Therefore, one could 
expect that the filtration window of the process could be as high 
as 60 to 80 minutes since the enantiomeric excess of the liquor is 
then maximized.26 However, the optical purity in the solid phase 
in Figure 3b indicates a gradual decrease of the crystal 
enantiomeric purity with process time. XRPD analyses of the 
crystals filtered at 15 and 30 minutes reveals that this is due to the 
spontaneous crystallization of the racemic compound RC-PXL 
after approximately 20 minutes (Figure S4) This shows that the 
introduction of PE-PXL facilitates the formation of RC-PXL 
crystals, probably through a heterogeneous nucleation mecha-
nism. Consequently, the filtration window was set at 20 or 30 
minutes rather than 60-80 min to compromise between the purity 
and the mass of the collected solid.  
 
 Figure 3. Evolution of enantiomeric excess of preferential crystal-
lization in SIPC mode starting from racemic conditions monitor-
ing (a): the liquid phase enriched with (S)-PXL after seeding with 
50 mg, 80 mg, 100 mg and 150 mg of (S)-PXL and (b) the solid 
phase with 80 mg of (S)-seeds. The vertical green line crossing 
the point t = 20 minutes taken as filtration window shows the time 
required to produce (S)-PXL with good purity with steadily in-
creasing the excess of (R)-PXL in the liquid phase.  
The experimental results for 4 consecutive SIPC cycles are giv-
en in Table 3 and shows that PC of PXL is successful in these 
conditions since high enantiomeric purity crops can be produced. 
These results indicate that the increase in seed mass increases the 
deposition rate of the pure enantiomer, which is the amount of 
crystalline material in units of gram/second that is deposited, due 
to the higher surface area offered by the larger amount of seeds 
and also to the slow nucleation kinetics of RC-PXL during the 20 
first minutes. This significantly increases the enantiomeric excess 
of the liquid phase, thus accelerating the resolution process.  
Herein, it can be concluded that the seed mass affects the resolu-
tion rate and the yield of the produced solid in a SIPC mode. It 
can also be deduced from these data that the crystallization behav-
ior of PXL during the SIPC process is driven by the crystal 
growth and by the secondary nucleation of PE-PXL. This assump-
tion is supported by SEM observations made on seed crystals 
before and after entrainment from which it can be seen that PE-
PXL has crystallized on the surface of the seeds (Figure S5). This 
prompted us to perform the resolution by implementing a con-
trolled cooling profile with the aim of improving the efficiency of 
the process.  
  
 
 
Table 3. Experimental results of the SIPC cycles in IBA at 10 °C. eeo (%): initial enantiomer excess in the liquid phase, 
Wseeds: mass of seeds, tend: duration time in minutes, Wc.s and O.Pc.s: weight and optical purity of the collected solid with seeds 
included, WP.E.: weight of produced pure enantiomer, Yexp: experimental yield, eef (%): enantiomeric excess of the liquid 
phase at the end of the process.  
Run Num. eeo (%) Wseeds (mg) tend (min) Wc.s. (mg) O.Pc.s. (%) WP.E. (mg) Yexp (%) eef (%) 
1 0.00 (R) 50 20 65.5 (R) 89.3 8.49 4.74 (S) 1.30 
2 (S) 1.00 (S) 50 30 57.6 (S) 90.7 2.60 1.45 (R) 0.30 
3 0.00 (R) 80 20 108.0 (R) 92.9 19.86 11.10 (S) 2.25 
4 (S) 1.70 (S) 80 30 110.5 (S) 90.2 18.87 10.55 (R) 0.11 
5 0.00 (R) 100 20 145.3 (R) 91.7 32.84 18.36 (S) 4.29 
6 (S) 3.64 (S) 100 30 140.6 (S) 91.6 28.38 15.87 (R) 0.20 
7 0.00 (R) 150 20 212.2 (R) 91.3 43.73 24.45 (S) 5.10 
8 (S) 3.80 (S) 150 30 201.0 (S) 89.7 30.29 16.94 (R) 0.15 
 
3.2.3. Preferential Crystallization of PXL by S3PC. Com-
pared to SIPC, the S3PC process is assumed to provide advanced 
control over the supersaturation profile and therefore to favor a 
gentler crystallization behavior, reducing the likelihood of spon-
taneous nucleation. Figure 2 C) depicts a cyclic operation of the 
PC process in S3PC mode to produce both enantiomers for the 
first two runs. A supersaturated solution was prepared at 25 °C 
(Co = 8 w%), resulting in a supersaturation ratio of 2.3 at 25°C 
for the racemic compound RC-PXL which is identical to that 
applied for SIPC. Therefore, the supersaturation with reference to 
MC-PXL is 1.6 slightly lower than that employed for SIPC 
(SIPC=1.8) which creates a moderate variation of ca. 10 % com-
pared to SIPC. Starting at a lower supersaturation for MC-PXL 
constitutes an advantage for S3PC and thus the driving force of 
the crystallization is controlled by the cooling profile.  
The data of two successive S3PC cycles carried out by recy-
cling the mother liquor are reported in Table 4. Based on our 
SIPC results we have chosen seed masses in the range of 80-100 
mg. In the first cycle and starting from a racemic composition 
(point (a) in Figure 2.C) the solution is seeded with 100 mg PE-
PXL ((R)-PXL) and linearly cooled down to 10 °C. A cooling rate 
of 0.75 °C/min was applied. The solution moves from eea = 0% 
(point a in Figure 2.C) to eeb = 3.3% (point b in Figure 2.C) and is 
then filtered to collect 160.0 mg of crude crops with optical purity 
of 92.0%. After compensation with 47.0 mg of RC-PXL and with 
solvent, a new run can be performed (points c, d and e in Figure 
2.C) with a cooling profile of 0.375 °C/min.  A slower cooling 
profile was adapted in this case because we found that at least 40 
minutes of cooling are required in order to get a solution enriched 
with the opposite enantiomer (i.e. the required starting condition 
for the next run). Such a slow cooling profile, however, systemat-
ically resulted in the concomitant spontaneous nucleation of RC-
PXL. Compared to SIPC for which the nucleation of RC-PXL was 
sufficiently delayed at 10 °C, the higher nucleation rate of this 
phase in S3PC might be related to the higher concentration in 
solution (8 w% for S3PC vs 5 w% for SIPC as Co). 
This shows that the used conditions are not suited for S3PC. 
Additional experiments should be designed to implement this 
process under smoother conditions in order to assess the 
enantiomeric selectivity of S3PC and to reach an advanced control 
over the primary heterogeneous nucleation of RC-PXL. 
 
 
 
 
 
Table 4.Two successive S3PC cycles of PXL in IBA. eeo 
(%): initial enantiomer excess in the liquid phase, Wseeds: 
mass of seeds, tend: duration time in minutes,  Wc.s. and 
O.Pc.s: weight and optical purity of the collected solid with 
seeds included, WP.E.: weight of produced pure enantiomer, 
Yexp: experimental yield calculated compared to the theo-
retical yield of 33.125%, eef (%): enantiomeric excess of 
the liquid phase at the end of the process. 
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1 0.00 
100 
(R) 
20 160.0 
(R) 
92.0 
47.20 9.96 
(S) 
3.30 
2 
(S) 
2.30 
100 
(S) 
40 210.2 
(S) 
81.1 
70.47 14.97 
(R) 
1.53 
3 
(R) 
1.40 
80 
(R) 
40 134.2 
(R) 
81.2 
28.57 6.02 
(S) 
0.40 
4 
(S) 
0.20 
100 
(S) 
40 156.0 
(S) 
82.6 
28.85 6.08 
(R) 
1.85 
 
4. DISCUSSION 
Preferential Crystallization (PC) is assumed to be non-
applicable when a racemic mixture crystallizes as a stable racemic 
compound. In this work, it is demonstrated that this limitation can 
be overcome for proxyphylline. Even though scale-up was not 
performed and various experimental parameters might still be 
optimized, we obtained a proof of concept for implementation of 
PC in a system that crystallizes as a stable racemic compound. 
The key step of the development of PC in a metastable conglom-
erate system is the selection of a solvent in which the nucleation 
rate of the racemic compound is sufficiently low. A solvent selec-
tion method was therefore developed, mainly consisting of induc-
tion time measurements and preliminary tests of the entrainment 
effect. During the implementation of the PC process using both 
isothermal and polythermal modes, several critical factors were 
identified: (i) large MSZW that should exceed the ratio of solubil-
ity of conglomerate and racemic compound, and thus the absence 
of spontaneous nucleation of the racemic compound after seeding 
(ii) fast growth rate of enantiopure compound, (iii) optimal mass 
and quality of seeds. It is also noteworthy that a large MSZW is a 
required but insufficient criterion towards resolution since our 
results show that PC cannot be performed from two solvents 
exhibiting long IT (water and 1-propanol). 
5. CONCLUSION 
We show that it can be envisaged to widen the scope of prefer-
ential crystallization (PC) to racemic compound forming system. 
By inhibiting the nucleation of the stable racemic compound, it is 
possible to apply PC by seeding the supersaturated solution in the 
metastable zone with the pure enantiomer. The success of the 
entrainment effect depends on the nature of the solvent, the initial 
supersaturation, the initial enantiomeric excess in the solution and 
particularly on the seed amount. The large MSZW is necessary 
but does not appear to be the only factor enabling PC in this type 
of system since seeding with pure enantiomer can also trigger the 
primary heterogeneous nucleation of the racemic compound. 
Therefore, process optimization is mandatory for successful im-
plementation of the method proposed here, and further studies are 
in progress to optimize process parameters such as stirring mode, 
supersaturation, temperature, cooling profile, mixture of solvents, 
and also seed quality. Although the method developed herein 
should be validated using more chiral compounds, the present 
work suggests new perspectives toward a possible enlargement of 
the application field of PC. 
 
LIST OF SYMBOLS AND ABREVIATIONS 
T (°C)   Temperature 
       Solubility ratio 
 Supersaturation 
w%      Weight percent 
ti Induction time 
Tc Crystallization temperature  
Ts Saturation temperature 
Co Initial concentration  
PC           Preferential crystallization 
DMSO    Dimethyl sulfoxide 
DMF       Dimethylformamide 
IBA Isobutyl alcohol 
MSZW    Metastable zone width 
ee Enantiomeric excess 
RC Racemic compound 
PE Pure enantiomer 
MC Metastable conglomerate 
DPL Diprophylline 
PXL Proxyphylline 
SIPC Seeded isothermal preferential crystallization 
S3PC Seeded polythermic programmed preferential 
crystallization 
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